Based on this rationale, we evaluated the efficacy of combining albumin-bound paclitaxel and S-1 with camrelizumab for the first-line treatment of G/GEJ adenocarcinoma. This evidence concerns the gene ALB and gastroesophageal junction adenocarcinoma.